Evidence map›Paper›PMID 39610815›Full record

ArticleRSC advances2024

Anti-hepatocellular carcinoma activities of novel hydrazone derivatives

Ahmed Nabil, Marwa Abdel-Motaal, Ayman Hassan, Mohamed M Elshemy, Medhat Asem, Mariam Elwan, Mitsuhiro Ebara, Mohammed Abdelmageed, Gamal Shiha, Hassan M E Azzazy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ahmed NabilResearch Center for Macromolecules and Biomaterials, National Institute for Materials Science (NIMS) Tsukuba 305-0044 Japan TOLBA.AhmedNabil@nims.go.jp +201000618349.ORCID https://orcid.org/0000-0002-5617-4726
Marwa Abdel-MotaalDepartment of Chemistry, College of Science, Qassim University Qassim Buraydah 51452 Saudi Arabia ma.mohammed@qu.edu.sa +966569909737.
Ayman HassanEgyptian Liver Research Institute and Hospital (ELRIAH) Sherbin El Mansoura Egypt.
Mohamed M ElshemyFaculty of Science, Menoufia University Menoufia Egypt.
Medhat AsemDepartment of Civil Engineering, College of Engineering and Information Technology, Onaizah Colleges Qassim Saudi Arabia.
Mariam ElwanEgyptian Ministry of Health El Mansoura Dakahlia Egypt.
Mitsuhiro EbaraResearch Center for Macromolecules and Biomaterials, National Institute for Materials Science (NIMS) Tsukuba 305-0044 Japan TOLBA.AhmedNabil@nims.go.jp +201000618349.ORCID https://orcid.org/0000-0002-7906-0350
Mohammed AbdelmageedDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Buraydah Colleges Qassim Saudi Arabia.
Gamal ShihaEgyptian Liver Research Institute and Hospital (ELRIAH) Sherbin El Mansoura Egypt.
Hassan M E AzzazyDepartment of Chemistry, School of Sciences & Engineering, The American University in Cairo New Cairo 11835 Egypt hazzazy@aucegypt.edu +201000565727.ORCID https://orcid.org/0000-0003-2047-4222

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related morbidity worldwide. Sorafenib is a first-line drug for the treatment of HCC, however, it is reported to cause serious adverse effects and may lead to resistance in many patients. In this study, 20 hydrazone derivatives incorporating triazoles, pyrazolone, pyrrole, pyrrolidine, imidazoline, quinazoline, and oxadiazine moieties were designed, synthesized, and characterized. In addition to molecular docking and

Identifiers

PMID39610815
PMCPMC11603412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.